Vaccitech promotes Gemma Brown to CFO, replacing Georgy Egorov

Barinthus Biotherapeutics plc.

Gemma Brown, previously Head of Financial Reporting, appointed CFO effective Sept 15, 2022; age 32.
She receives £220k base salary and is eligible for annual bonus up to 40% of base.
Prior CFO Georgy Egorov terminated Sept 14, 2022; termination unrelated to financials or controls.
Egorov receives six months base salary severance; Brown entitled to similar payment on termination.
Brown joined Vaccitech in Sept 2021; prior experience as Senior Manager at EY.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Gemma Brown

Chief Financial Officer

BRNS · Barinthus Biotherapeutics plc.

Effective: 2022-09-15
Successor: Georgy Egorov
Filed: September 20, 2022, 7:59 PM ET

Effective September 15, 2022, the Board of Directors (the “Board”) of Vaccitech plc (the “Company”) appointed Gemma Brown, age 32, as the Company’s Chief Financial Officer.

Departed

Georgy Egorov

Chief Financial Officer

BRNS · Barinthus Biotherapeutics plc.

Effective: 2022-09-14
Successor: Gemma Brown
Filed: September 20, 2022, 7:59 PM ET

On September 14, 2022, the Company terminated the employment of Georgy Egorov in its entirety, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Gemma Brown was appointed as Chief Financial Officer at Barinthus Biotherapeutics plc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

Effective September 15, 2022, the Board of Directors (the “Board”) of Vaccitech plc (the “Company”) appointed Gemma Brown, age 32, as the Company’s Chief Financial Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Georgy Egorov was terminated as Chief Financial Officer at Barinthus Biotherapeutics plc..

Action: terminated
Role: Chief Financial Officer

Exact text from the filing

On September 14, 2022, the Company terminated the employment of Georgy Egorov in its entirety, effective immediately.

View on SEC.gov

Barinthus Biotherapeutics plc. filing history →

Source: SEC EDGAR

accession 0001104659-22-101580

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.